

## WEST Search History

DATE: Monday, September 29, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	

*DB=USPT; PLUR=YES; OP=OR*

L4	L2 and exendin	7	L4
L3	L2 and glucagon	231	L3
L2	memory or learning or cognition	432284	L2
L1	gilatide	0	L1

END OF SEARCH HISTORY

=> d his

(FILE 'HOME' ENTERED AT 10:38:23 ON 29 SEP 2003)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 10:38:37 ON 29 SEP 2003

L1 966 S GLACAGON OR EXENDIN  
L2 102695 S GLUCAGON OR EXENDIN  
L3 336650 S L2 AND MEMORY OR LEARNING OR COGNITION  
L4 557198 S MEMORY OR LEARNING OR COGNITION  
L5 1157 S L4 AND GLUCAGON OR EXENDIN  
L6 2 S L5 AND GILATIDE  
L7 3 S GILATIDE

Db 1 HSEGFTSD 9

RESULT 4  
AAW39338

ID AAW39338 standard; peptide; 30 AA.

XX

AC AAW39338;

XX

DT 25-MAR-2003 (updated)

DT 05-JUN-1998 (first entry)

XX

H. horridum exendin-3 peptide derivative #7.

XX

DE H. horridum exendin-3 peptide derivative #7.

XX

KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX

OS Heloderma horridum.

XX

FH Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX

FN W09746584-A1.

XX

PD 11-DEC-1997.

XX

PF 05-JUN-1997; 97WO-EP02930.

XX

PR 05-JUN-1996; 96DE-1022502.

XX

PR 13-SEP-1996; 96DE-1037230.

XX

PA (BOEFL) BOEHRINGER MANNHEIM GMBH.

XX

PI Goekke B, Goekke R, Hoffmann E;

XX

DR WPI; 1998-042119/04.

XX

PT Truncated versions of exendin peptide(s) for treating diabetes -  
PT increase secretion and biosynthesis of insulin, but reduce those of  
PT glucagon, and do not induce hypoglycaemia

XX

PS Claim 2; Page 26; 150pp; English.

XX

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method

CC for the treatment of diabetes mellitus. These peptides can stimulate

CC biosynthesis and secretion of insulin, but have the opposite effect on

CC glucagon, and independent of this activity can increase peripheral

CC glucose utilisation. Exendin-3 and exendin-4 are only active when blood

CC sugar levels are high, so they will not induce hypoglycaemia. Compared

CC with glucagon-like peptide 1 (GLP-1) and the known exendins, they are

CC more active (effective at lower doses), more stable to degradation and

CC metabolism and have a longer lasting effect. Truncated forms of this

CC peptide can be made more economically than full length versions.

CC (Updated on 25-MAR-2003 to correct PR field.)

XX

SQ Sequence 30 AA;

XX

QY 1 HSEGFTSD 9

DB 1 HSEGFTSD 9

XX

Query Match 100.0%; Score 49; DB 19; Length 30;

Best Local Similarity 100.0%; Pred. No. 0.03%; Mismatches 0; Indels 0; Gaps 0;

AC AAW39331

ID AAW39331 standard; peptide; 30 AA.

XX

RESULT 5

AAW39331

ID AAW39331 standard; peptide; 30 AA.

XX

DE An insoluble glucagon-like peptide 1 (GLP-1) compound.

AC AAW393331;

XX

DT 25-MAR-2003 (updated)

DT 05-JUN-1998 (first entry)

XX

H. horridum exendin-4 peptide derivative #25.

XX

DE Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX

OS Heloderma horridum.

XX

FH Key Location/Qualifiers

FT Modified-site 14

FT /label= Nle

FT /note= "norleucine"

XX

FT Modified-site 30

FT /note= "C-terminal amide"

XX

PN W09746584-A1.

XX

PD 11-DEC-1997.

XX

PF 05-JUN-1997; 97WO-EP02930.

XX

PR 05-JUN-1996; 96DE-1022502.

XX

PR 13-SEP-1996; 96DE-1037230.

XX

PA (BOEFL) BOEHRINGER MANNHEIM GMBH.

XX

PI Goekke B, Goekke R, Hoffmann E;

XX

DR WPI; 1998-042119/04.

XX

PT Truncated versions of exendin peptide(s) for treating diabetes -  
PT increase secretion and biosynthesis of insulin, but reduce those of  
PT glucagon, and do not induce hypoglycaemia

XX

PS Claim 2; Page 25; 150pp; English.

XX

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method

CC for the treatment of diabetes mellitus. These peptides can stimulate

CC biosynthesis and secretion of insulin, but have the opposite effect on

CC glucagon, and independent of this activity can increase peripheral

CC glucose utilisation. Exendin-3 and exendin-4 are only active when blood

CC sugar levels are high, so they will not induce hypoglycaemia. Compared

CC with glucagon-like peptide 1 (GLP-1) and the known exendins, they are

CC more active (effective at lower doses), more stable to degradation and

CC metabolism and have a longer lasting effect. Truncated forms of this

CC peptide can be made more economically than full length versions.

CC (Updated on 25-MAR-2003 to correct PR field.)

XX

SQ Sequence 30 AA;

XX

QY 1 HSEGFTSD 9

DB 1 HSEGFTSD 9

XX

Query Match 100.0%; Score 49; DB 19; Length 30;

Best Local Similarity 100.0%; Pred. No. 0.03%; Mismatches 0; Indels 0; Gaps 0;

AC AAG63289

ID AAG63289

AC AAG63289;

ID 01-OCT-2001 (first entry)

XX

DE An insoluble glucagon-like peptide 1 (GLP-1) compound.

AC AAG63289

ID AAG63289

AC AAG63289;

ID 01-OCT-2001

XX

DE An insoluble glucagon-like peptide 1 (GLP-1) compound.